Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 1
2013 1
2015 1
2016 3
2017 2
2018 2
2019 3
2020 1
2021 1
2022 1
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.
Vissing CR, Axelsson Raja A, Day SM, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Bundgaard H, Orav EJ, Ho CY; Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators. Vissing CR, et al. JAMA Cardiol. 2023 Nov 1;8(11):1083-1088. doi: 10.1001/jamacardio.2023.2808. JAMA Cardiol. 2023. PMID: 37672268 Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: The multicenter, double-blind, placebo-controlled Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) randomized clinical trial was conducted from April 2014 to July 2019 at 17 sites in 4 c …
DESIGN, SETTING, AND PARTICIPANTS: The multicenter, double-blind, placebo-controlled Valsartan for Attenuating Disease Evolution in Early Sa …
Transforming Growth Factor-beta Analysis of the VANISH Trial Cohort.
Kim Y, Mastali M, Van Eyk JE, Orav EJ, Vissing CR, Day SM, Axelsson Raja A, Russell MW, Zahka K, Lever HM, Pereira AC, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Soslow JH, Becker JR, Seidman CE, Ho CY; VANISH Investigators. Kim Y, et al. Circ Heart Fail. 2023 Apr;16(4):e010314. doi: 10.1161/CIRCHEARTFAILURE.122.010314. Epub 2023 Mar 31. Circ Heart Fail. 2023. PMID: 36999957 Free PMC article. No abstract available.
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.
Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL; VANISH Investigators; Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Ho CY, et al. Nat Med. 2021 Oct;27(10):1818-1824. doi: 10.1038/s41591-021-01505-4. Epub 2021 Sep 23. Nat Med. 2021. PMID: 34556856 Free PMC article. Clinical Trial.
Milk-Alkali Syndrome.
Ali R, Hashmi MF, Patel C. Ali R, et al. 2023 Feb 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Feb 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32491432 Free Books & Documents.
With the advent of newer drugs for treating peptic ulcer disease, such as histamine type-2 receptor blockers, in the 1980s, the syndrome virtually vanished from the world. Recently, however, an increased number of cases of milk-alkali syndrome have been reported. ...
With the advent of newer drugs for treating peptic ulcer disease, such as histamine type-2 receptor blockers, in the 1980s, the syndrome vir …
Baseline Characteristics of the VANISH Cohort.
Axelsson Raja A, Shi L, Day SM, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall EK, Becker J, Jefferies JL, Patel AR, Choudhury L, Murphy AM, Canter C, Bach R, Taylor M, Mestroni L, Wheeler MT, Benson L, Owens AT, Rossano J, Lin KY, Pahl E, Pereira AC, Bundgaard H, Lewis GD, Vargas JD, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E, Ho CY. Axelsson Raja A, et al. Circ Heart Fail. 2019 Dec;12(12):e006231. doi: 10.1161/CIRCHEARTFAILURE.119.006231. Epub 2019 Dec 9. Circ Heart Fail. 2019. PMID: 31813281 Free PMC article. Clinical Trial.
BACKGROUND: The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease progr …
BACKGROUND: The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted y …
Gross Motor Function in Pediatric Onset TUBB4A-Related Leukodystrophy: GMFM-88 Performance and Validation of GMFC-MLD in TUBB4A.
Gavazzi F, Patel V, Charsar B, Glanzman A, Erler J, Sevagamoorthy A, McKenzie E, Kornafel T, Ballance E, Pierce SR, Teng M, Formanowski B, Woidill S, Shults J, Wassmer E, Tonduti D, Magrinelli F, Bernard G, Van Der Knaap M, Wolf N, Adang L, Vanderver A. Gavazzi F, et al. J Child Neurol. 2023 Aug;38(8-9):498-504. doi: 10.1177/08830738231188159. Epub 2023 Jul 17. J Child Neurol. 2023. PMID: 37461315 Free PMC article.
Oncocytoma: the vanishing parotid mass.
Patel ND, van Zante A, Eisele DW, Harnsberger HR, Glastonbury CM. Patel ND, et al. AJNR Am J Neuroradiol. 2011 Oct;32(9):1703-6. doi: 10.3174/ajnr.A2569. Epub 2011 Jul 14. AJNR Am J Neuroradiol. 2011. PMID: 21757520 Free PMC article.
Stacking angle-tunable photoluminescence from interlayer exciton states in twisted bilayer graphene.
Patel H, Huang L, Kim CJ, Park J, Graham MW. Patel H, et al. Nat Commun. 2019 Mar 29;10(1):1445. doi: 10.1038/s41467-019-09097-x. Nat Commun. 2019. PMID: 30926775 Free PMC article.
This peak splitting provides independent estimates of the exciton binding energy which scales from 0.5-0.7 eV with teta = 7.5 to 16.5. A predicted vanishing exciton-continuum coupling strength helps explain both the weak resonant PL and the slower 1 ps(-1) exciton relaxati …
This peak splitting provides independent estimates of the exciton binding energy which scales from 0.5-0.7 eV with teta = 7.5 to 16.5. A pre …
A Disquiet Find: Anabolic-androgenic steroids and Vanishing Bile Duct Syndrome.
Kalal C, Wagh A, Patel A, Joshi H, Surude R, Singh A, Bhatia S, Bhatt C. Kalal C, et al. Hepatol Forum. 2020 Sep 21;1(3):109-111. doi: 10.14744/hf.2020.2020.0021. eCollection 2020 Sep. Hepatol Forum. 2020. PMID: 35949722 Free PMC article.
Steroid-induced liver diseases may range from chronic hepatitis to vascular or bile ductular injury and death. Presented herein is a case of Vanishing Bile Duct Syndrome due to the anabolic steroid consumption by a young, healthy male....
Steroid-induced liver diseases may range from chronic hepatitis to vascular or bile ductular injury and death. Presented herein is a case of …
23 results